Semaglutide: EMA Safety Probe Confirms Rare Eye Disorder Risk

The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”